Moderna, Inc. (NASDAQ:MRNA) | Finanzwire

Basculer en Français

8299	Companies
114942	Keywords
55348	Articles
62469	Press releases

Home
Companies
Moderna, Inc.

BRIEF

published on 10/17/2024 at 13:10, 1 month 4 days ago

Moderna to Announce Q3 2024 Financial Results

Financial Results Conference Call Webcast Moderna Third Quarter 2024
PRESS RELEASE

published on 10/17/2024 at 13:05, 1 month 4 days ago

Moderna to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024
Moderna, Inc. to host live conference call and webcast on Nov 7, 2024 to report Q3 financial results and provide corporate update. Leading in mRNA medicine innovation

Innovation Financial Results Conference Call MRNA Medicine Moderna
BRIEF

published on 10/02/2024 at 13:05, 1 month 19 days ago

Abbas Hussain Joins Moderna's Board of Directors

Board Of Directors Healthcare Leadership Moderna Abbas Hussain Vaccine Commercialization
PRESS RELEASE

published on 10/02/2024 at 13:00, 1 month 19 days ago

Abbas Hussain Joins Moderna's Board of Directors
Abbas Hussain joins Moderna's Board of Directors, bringing 35 years of healthcare leadership experience. Moderna aims for continued growth with strategic insights and global expertise

Board Of Directors Healthcare Leadership Moderna Abbas Hussain Global Commercialization
BRIEF

published on 10/01/2024 at 02:05, 1 month 20 days ago

Moderna and Cenra Healthcare Enter Joint Agreement to Promote mRNA Vaccines in Taiwan

COVID-19 Moderna MRNA Vaccines Taïwan Cenra Healthcare
PRESS RELEASE

published on 10/01/2024 at 02:00, 1 month 20 days ago

Moderna and Cenra Healthcare Enter Joint Agreement to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Taiwan, Including COVID-19 Vaccines
Moderna Inc. and Cenra Healthcare enter joint agreement to co-promote mRNA respiratory vaccine portfolio in Taiwan, enhancing public health initiatives. Details undisclosed

Moderna Taïwan MRNA Vaccine Cenra Healthcare Joint Agreement
BRIEF

published on 09/30/2024 at 13:05, 1 month 21 days ago

Moderna Doses First Participant in Phase 3 Trial of Norovirus Vaccine

Moderna Phase 3 Trial Vaccine Development MRNA Norovirus
PRESS RELEASE

published on 09/30/2024 at 13:00, 1 month 21 days ago

Moderna Announces First Participant Dosed in Pivotal Phase 3 Trial of Investigational mRNA Norovirus Vaccine, mRNA-1403
Moderna initiates Phase 3 trial for mRNA-1403, an investigational norovirus vaccine, aiming to prevent infection from norovirus. Global recruitment has started

Moderna Phase 3 Trial MRNA-1403 Norovirus Vaccine Global Recruitment
BRIEF

published on 09/17/2024 at 17:05, 2 months 3 days ago

Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant

COVID-19 Vaccine Health Canada Moderna Spikevax KP.2 Variant
PRESS RELEASE

published on 09/17/2024 at 17:00, 2 months 3 days ago

Moderna Receives Health Canada Approval For Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older
Moderna's SPIKEVAX® KP.2 variant COVID-19 vaccine authorized in Canada for 2024-2025 season to protect against COVID-19 strains. Delivery to begin promptly for vaccination campaigns

COVID-19 Vaccine Health Canada Moderna Spikevax Vaccination Campaigns

Accesswire

Published on 11/21/2024 at 14:15, 16 minutes ago

neurocare Group AG Welcomes Kevin Reeder as Chief Financial Officer
Published on 11/21/2024 at 14:00, 31 minutes ago

Demotech, Inc. Assigns a Financial Stability Rating(R) of A, Exceptional, to Steadily Insurance Company
Published on 11/21/2024 at 14:00, 31 minutes ago

Montara Raises $5.4M to Help Organizations Deliver Better Data Products Faster
Published on 11/21/2024 at 14:00, 31 minutes ago

Tevir Capital LP Ltd. Updates Early Warning Reporting in Respect of VerticalScope Holdings Inc.
Published on 11/21/2024 at 14:00, 31 minutes ago

GameSquare's Stream Hatchet Publishes Q3 Report

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 14:16, 15 minutes ago

EQS-Adhoc: LM PAY S.A. Announces Third Quarter 2024 Preliminary Results and Updated Guidance
Published on 11/21/2024 at 14:15, 16 minutes ago

ZenaTech Signs Blue UAS and NDAA Compliant Supply Chain Partners to Sell to US Defense Branches and NATO Forces
Published on 11/21/2024 at 14:00, 31 minutes ago

Form 8.3 - LOYS AG: Learning Technologies Group plc
Published on 11/21/2024 at 13:15, 1 hour 16 minutes ago

NOTICE OF ANNUAL GENERAL MEETING
Published on 11/21/2024 at 12:35, 1 hour 56 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6

Les Echos

Published on 11/21/2024 at 06:58, 7 hours 33 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 19 hours 11 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 46 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 46 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE